Aktuellt
SENASTE
Redeye’s initial takeaway is that both the lead project Mangoral (contrast agent addressing liver metastases) and Oncoral (improved efficacy and tolerability for chemotherapy addressing metastatic gastric cancer) remain on track and that Ascelia’s newly opened US Office supports the direct US sales strategy for the US launch in late 2022 or early 2023.
LÄS MER
